You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 5,604,199


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,604,199
Title: Method of treating fibrosis in skeletal muscle tissue
Abstract:A method of treating skeletal muscle fibrosis in mammals. The novel method is effective for reducing the extent of skeletal muscle fibrosis in an individual who suffers from a disorder which targets skeletal muscle tissue, such as Duchenne\'s and Becker\'s muscular dystrophy and denervation atrophy induced by either trauma or neuromuscular disease. The treatment includes administering to the individual an effective amount of a metalloporphyrin compound, especially hemin, heme arginate, cobalt protoporphyrin IX chloride and cobalt protoporphyrin IX arginate.
Inventor(s): Funanage; Vicky L. (Wilmington, DE)
Assignee: The Nemours Foundation (Wilmington, DE)
Application Number:08/543,812
Patent Claims:1. A method of treating skeletal muscle fibrosis in mammals comprising the steps of

(A.) identifying an individual suspected of suffering from a disorder targeting skeletal muscle tissue, and

(B.) administering to such individual an effective amount of pharmaceutical composition that includes at least one metalloporphyrin compound to reduce the rate of skeletal muscle fibrotic tissue growth.

2. The method of claim 1 wherein the mammals are humans.

3. The method of claim 2 wherein the disorder targeting skeletal muscle tissue is selected from the group consisting of muscular dystrophy; denervation atrophy induced by neuromuscular disease; and traumatic injury-induced denervation atrophy.

4. The method of claim 3 wherein the disorder targeting skeletal muscle tissue is Duchenne's muscular dystrophy or Becker's muscular dystrophy.

5. The method of claim 4 wherein the disorder targeting skeletal muscle tissue is Becker's muscular dystrophy.

6. The method of claim 3 wherein the disorder targeting skeletal muscle tissue is a neuromuscular disease selected from the group consisting of acute polyneuritis; poliomyelitis; Werdig/Hoffman disease; amyotrophic lateral sclerosis; and progressive bulbar atrophy disease.

7. The method of claim 3 wherein the disorder targeting skeletal muscle tissue is a traumatic injury-induced denervation atrophy.

8. The method of claim 2 wherein the metalloporphyrin compound is an organic radical substituted porphine complexed with a cationic metal atom bonded to a functional moiety.

9. The method of claim 8 wherein the cationic metal atom is selected from the group consisting of elements of Group VIII of the periodic table.

10. The method of claim 9 wherein the cationic metal atom is iron.

11. The method of claim 9 wherein the cationic metal atom is cobalt.

12. The method of claim 8 wherein the organic radical substituted porphine is a protoporphyrin IX radical.

13. The method of claim 12 wherein the cationic metal atom is selected from the group consisting elements of Group VIII of the periodic table.

14. The method of claim 13 wherein the cationic metal atom is selected from the group consisting of iron, cobalt, platinum, palladium, ruthenium and rhodium.

15. The method of claim 13 wherein the functional moiety is selected from the group consisting of a halogen, an amino acid residue, a lower alkyl group, a hydroxyl group and a lower oxylated alkyl group.

16. The method of claim 15 wherein the functional moiety is selected from the group consisting of chlorine, bromine, iodine, arginine residue (arginate), lysine residue and a hydroxyl group.

17. The method of claim 2 wherein the metalloporphyrin compound is selected from the group consisting of hemin, heme arginate, cobalt protoporphyrin IX chloride, and cobalt protoporphyrin IX arginate.

18. A method of treating skeletal muscle fibrosis in mammals comprising the steps of

(A.) identifying an individual suspected of suffering from a disorder targeting skeletal muscle tissue;

(B.) determining a base state of skeletal muscle fibrosis of the individual;

(C.) administering a pharmaceutical formulation comprising at least one metalloporphyrin compound to the individual at a preselected frequency and a preselected amount;

(D.) determining a treated state of skeletal muscle fibrosis exhibited by the individual at a later time;

(E.) changing the administration of metalloporphyrin compound according to only one of:

(1.) increasing administration of the metalloporphyrin compound if the treated state demonstrated an increase of skeletal muscle fibrosis relative to the base state; and

(2.) maintaining or decreasing administration of the metalloporphyrin, if the treated state demonstrated no increase of skeletal muscle fibrosis relative to the base state; and

(F.) repeating steps (B) through (E).

19. The method of claim 18 wherein the preselected amount is in the range of about 0.25 to about 20 mg/kg of body weight administered within a 24 hour period and the preselected frequency is once about every 5-9 days.

20. The method of claim 18 wherein the metalloporphyrin compound is selected from the group consisting of hemin, heme arginate, cobalt protoporphyrin IX chloride, and cobalt protoporphyrin IX arginate.

21. The method of claim 18 wherein the pharmaceutical composition is administered by intravenous infusion.

22. The method of claim 21 wherein the metalloporphyrin compound is heme arginate.

23. The method of claim 20 wherein the metalloporphyrin compound is cobalt protoporphyrin IX chloride or cobalt protoporphyrin IX arginate.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.